8 January 2021
Byotrol Plc
("Byotrol" or the "Group")
Capital reduction
Byotrol plc (AIM: BYOT), the anti-microbial technology company, announces that on 8 December 2020 the High Court issued an order confirming the cancellation of the Company's share premium account and the B shares issued by the Company to capitalise the amount standing to the credit of the merger reserve of the Company ("the Capital Reduction"). Following registration with Companies House, the Capital Reduction became effective on 7 January 2021.
For further information contact:
| Byotrol Plc |
|
| David Traynor, Chief Executive | +44 (0)1925 742 000 |
| Nic Hellyer, Chief Financial Officer |
|
|
|
|
| finnCap Limited (Nominated Adviser and Broker) | +44 (0)20 7220 0500 |
| Geoff Nash/Kate Bannatyne - Corporate Finance |
|
| Richard Chambers - ECM |
|
|
|
|
| Flagstaff Strategic and Investor Communications | +44 (0)20 7129 1474 |
| Tim Thompson/Andrea Seymour/Fergus Mellon
|
|
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to byotrol.co.uk
[END]
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
